Torrent Pharma has reported Rs 2,291 crore in its consolidated revenue, a 7 per cent jump year on year in the September quarter from Rs 2,137 crore in the same quarter last year.
The pharma company’s net profit slumped by 1 per cent year on year (YoY) and stood at Rs 312 crores in the second quarter from Rs 316 crores in the previous year.
EBITDA margins also fell by 2 per cent year on year to Rs 694 crore from 711 crores in the Financial Year 2022.
Torrent Pharma’s R&D figures also reduced by 7 per cent YoY to be recorded at Rs 121 crore in the current quarter compared to the corresponding quarter where the company spent Rs 130 crores.
The company’s revenue from India grew by 13 per cent to Rs 1,224 crores, while the revenue from Brazil stood at Rs 185 crores seeing a growth of 19 per cent in the September quarter.
Whereas US revenue stood at Rs 292 crores, up by 3 per cent and Germany revenue at Rs 220 crores down by 12 per cent for the current quarter.
The company has said in a statement that its growth in the quarter was aided by new launches, the performance of top brands and market outperformance across focus therapies and the Acquisition of Curatio Healthcare which was completed on 14th October 2022.